gamma secretase inhibitor – Talk Bio

Actionable Insights Powered by AI

Immunome’s desmoid tumor drug varegacestat posts landmark Phase 3 results, setting up a potential challenge to Merck KGaA’s Ogsiveo

16 hours ago talkbio0Tagged Fibromatosis, Aggressive, Frequency of Responses, gamma secretase inhibitor, Immunome, Infrequent, Merck KGaA, NDA, Neoplasms, Ogsiveo, Phase 3 RINGSIDE trial, Progression-Free Survival, varegacestat

Immunome; varegacestat; desmoid tumors; Phase 3 RINGSIDE trial; gamma secretase inhibitor; Merck KGaA; Ogsiveo; progression-free survival; objective response rate; rare tumors; oncology; NDA filing